Antibiotic-Associated Diarrhea | CMAC

Antibiotic-Associated Diarrhea

Clinical Microbiology and Antimicrobial Chemotherapy. 2002; 4(1):22-32

​ Malov V.A.
antibiotic-associated diarrhea Clostridium difficile pseudomembranous colitis antimicrobial therapy
Section
Diseases and Pathogens
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2002; 4(1):22-32

Abstract

Diarrhea, which is associated with the usage of antimicrobials, is one of the important problems in clinical practice. This article reviews the questions of etiology, pathogenesis and epidemiology of antibiotic-associated diarrhea (AAD). Clinical forms and features of the AAD are discussed. Advantages and disadvantages of different microbiological diagnostics for Clostridium difficile infection, which is the most common cause of the AAD are also analyzed. The main approaches to the management of Clostridium difficile colitis, indications for use ofantibacterial therapy and problems of the choice of antimicrobials are presented.

  • 1. Навашин С.М. Введение. Рус мед журн 1997; 5(21):1364.
  • 2. McFarland L.V. Diarrhea acquired in the hospital. Gastroenterol Clin North Am 1993; 22:563-77.
  • 3. Малов В.А., Пак С.Г., Несвижский Ю.В., Кондратьева Т.В. Диагностика антибиотикоассоциированных колитов, обусловленных Clostridium difficile. Материалы VI Российско-итальянской научной конференции "Инфекционные болезни: диагностика, лечение, профилактика". 2000; Санкт-Петербург, Россия. с. 156.
  • 4. Thielman N.M. Antibiotic-associated colitis. In: Mandell G.L., Bennett J.E., Dolin R., editors. Principles and practice of infectious diseases. 5th ed. Philadelphia: Churchill Livingstone; 2000. p. 1111-26.
  • 5. George W.L., Rolfe R.D., Finegold S.M. Clostridium difficile and its cytotoxin in feces of patients with antimicrobial agent-associated diarrhea and miscellaneous conditions. J Clin Microbiol 1982; 15:1049-53.
  • 6. Benoit R., Dorval D., Loulergue J., et al. Post-antibiotic diarrheas: role of Klebsiella oxytoca. Gastroenterol Clin Biol 1992; 16:860-4.
  • 7. Hogenauer C., Hammer H., Krejs G. Mechanisms and management of antibiotico-associated diarrhea. Clin Inf Dis 1998; 27:702-10.
  • 8. Holmberg S.D., Oslterholm M.T., Senger K.A. Drag-resistant Salmonella from animal fed antimicrobials. N Engl J Med 1984; 311:617-22.
  • 9. McDonald M., Ward P., Harvey K. Antibiotic-associated diarrhoea and methicillin-resistant Staphylococcus aureus. Med J Aust 1982; 1:462-4.
  • 10. Reinke C.M. ASHP therapeutic position statement on the preferential use of metronidazole for the treatment of Clostridium difficile-associated disease. Am J Health-Syst Pharm 1998; 55:1407-11.
  • 11. Taylor M., Ajayi F., Almond M. Enterocolitis caused by methicillin-resistant Staphylococcus aureus. Lancet 1993; 342:804.
  • 12. Prescott R.J., Harris M., Banejee S.S. Funginal infections of the small and large intestine. J Clin Pathol 1992; 45:806-11.
  • 13. Bartlett J.G. Antibiotic-associated diarrhea. N Engl J Med 2002; 346:334-9.
  • 14. Hogenauer C., Hammer H.F., Krejs G.J., Reisinger E.C. Mechanisms and management of antibiotic-associated diarrhea. Clin Infect Dis 1998; 27:702-10.
  • 15. Chassany O., Michaux A., Bergmann J.F. Drug-induced diarrhoea. Drug Saf 2000; 22:53-72.
  • 16. Riley T.V. Clostridium difficile: A pathogen of the nineties. Eur J Clin Microbiol Infect Dis 1998; 17:137-41.
  • 17. Kim K.H., Fekety R., Batts D.H., et al. Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic-associated colitis. J Infect Dis 1981; 143:42-50.
  • 18. Larson H.E. Barclay F.E., Honour P. et all. Epidemiology of Clostridium difficile in infants. J Infect Dis 1982; 146:727-33.
  • 19. Frost F., Craun G.F., Calderon R.L. Increasing hospitalization and death possibly due to Clostridium difficile diarrheal disease. EID 1998; 4(3):619-25.
  • 20. Hirschhorn L.R., Trnka Y., Onderdonk A., et al. Epidemiology of community-acquired Clostridium difficile-associated diarrhea. J Infect Dis 1994; 169:127-33.
  • 21. McFarland L.V., Mulligan M.E., Kwok R.Y., Stamm W.E. Nosocomial acquisition of Clostridium difficile in infection. N Engl J Med 1989; 320:204-10.
  • 22. Spencer RC. The role of antimicrobial agents in the aetiology of Clostridium difficile-associated disease. J Antimicrob Chemother 1998; 41:21-7.
  • 23. Pierce P.F., Wilson R., Silwa J.J., et al. Antibiotic-associated pseudomembranous colitis: An epidemiologic investigation of claster of cases. J Infect Dis 1982; 145:269-74.
  • 24. Hutin Y., Molina J.M., Casin I., et al. Risk factors for Clostridium difficile-associated diarrhoea in HIV-infected patients. AIDS 1993; 7:1441-7.
  • 25. Hooper L.V., Wong M.H., Thelin A., et al. Molecular analysis of commensal host-microbial relationships in the intestine. Science 2001; 291:881-4.
  • 26. Small J.D. Drags used in hamsters with a review of antibiotic-associated colitis in the laboratory hamster. In: Van Hoosier G.L., McPherson C.W., editors. Laboratory Hamsters. Orlando: Academic Press; 1987. p.179-99.
  • 27. Depitre C., Delmee M., Avesani V., et al. Serogroup F strains Clostridium difficile of produce toxin B but not toxin A. J Med Mecrobiol 1993; 3:434-41.
  • 28. Hippenstiel S., Kratz T., Krull M., et al. Rho protein inhibition blocks protein kinase C translocation and activation. Biochem Biophys Res Commun 1998; 245:830-4.
  • 29. Viscidi R., Laughon B.E., Yoker R. Serum antibody response to toxin A and B of Clostridium difficile. J Infect Dis 1983; 148:93-100.
  • 30. Kelly C.P., Pothoulakis C., Orellana J., et al. Human colonic aspirates containing immunoglobulin A antibody to Clostridium difficile toxin A inhibit toxin A-receptor binding. Gastroenterology 1992; 102:35-40.
  • 31. Knoop F.C., Owens M., Crocker I.C. Clostridium difficile: Clinical disease and diagnosis. Clin Microbiol Rev 1993; 6:251-65.
  • 32. Manabe Y.C., Vinetz J.M., MooreR.D., et al. Clostridium difficile colitis: An efficient clinical approach to diagnosis. Ann Intern Med 1995; 123:835-40.
  • 33. Byl B., Jacobs F., Struelens M.J., Thys J.P. Extraintestinal infections Clostridium difficile. Clin Infect Dis 1995; 20:160-2.
  • 34. Do A.N., Fridkin S.K., Yechouron A., et al. Risk factors for early recurrent Clostridium difficile-associated diarrhea. Clin Infect Dis 1998; 26:954-9.
  • 35. Nair S., Yadav D., Corpuz M., et al. Clostridium difficile colitis: factors influencing treatment failure and relapse – a prospective evaluation. Am J Gastroenterol 1998; 93:1873-6.
  • 36. Kyne L., Warny M., Qamar A., Kelly C.P. Association Between Antibody Response to Toxin A and Protection Against Recurrent Clostridium difficile Diarrhoea. Lancet 2001; 357:189-93.
  • 37. Lyerly D.M., Krivan H.C., Wilkins T.D. Clostridium difficile: Its disease and toxins. Clin Microbiol Rev 1988; 1:1-18.
  • 38. Bergstein J.M., Kramer A., Wittman D.H., et al. Pseudomembranous colitis: How useful is endoscopy? Surg Endosc 1990; 4:217-9.
  • 39. Fekety R. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. American College of Gastroenterology. Practice Parameters Committee. Am J Gastroenterol 1997; 92:739-50.
  • 40. Teasley D.G., Gerding D.N., Olson M.M., et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile-associated diarrhoea and colitis. Lancet 1983; 2:1043-6.
  • 41. MacLaren R., Morton T.H., Kuhl D.A. Effective management of Clostridium difficile colitis. Hosp Pharm 1997; 32:1126-32.
  • 42. Elmer G.W., McFarland L.V., Surawicz C.M., Danko L., Greenberg R.N. Behaviour of Saccharomyces boulardii in recurrent Clostridium difficile disease patients. Aliment Pharmacol Ther 1999; 13(12):1663-8.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared